Search In this Thesis
   Search In this Thesis  
العنوان
Study of Interleukin 6 (IL-6) in chronic Lymphocytic Leukemia/
المؤلف
Fekry,Gehad Hamada
هيئة الاعداد
باحث / جهاد حماده فكرى
مشرف / عصام عبدالواحد حسن
مشرف / عماد عبد المحسن عبد الهادى
مشرف / محمد طريف محمد حمزة
مشرف / هناء فتحى عبد السميع
مشرف / مصطفى كمال الرزاز
تاريخ النشر
2018
عدد الصفحات
204.p:
اللغة
الإنجليزية
الدرجة
الدكتوراه
التخصص
الطب الباطني
تاريخ الإجازة
13/6/2018
مكان الإجازة
جامعة عين شمس - كلية الطب - Internal Medicine
الفهرس
Only 14 pages are availabe for public view

from 204

from 204

Abstract

Background chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. These malignant B-CLL cells represent over 99% of peripheral blood mononuclear cells (PBMCs) in CLL patients. In case of an aggressive form, the cell number may quickly double and, as a result, the disease may be fatal within a relatively short period of time .Currently several biomarkers are being used as CLL prognosticators, including: elevated protein levels (e.g. TCL-1, ZAP-70, CD38), elevated RNA levels (e.g. CLLU1, LPL, miRNAs), gene mutations (e.g.TP53, SF3B1, BIRC3, NOTCH1) and epigenetic changes. Early reports implicated IL-6 as pro-tumorigenic factor in various human tumors. IL-6 levels increased significantly in serum of CLL patients and correlated with adverse clinical features and short survival.
Aim of the work: Is to evaluate IL 6 level in patients with CLL at time of presentation and 6 months after chemotherapy and to study its relevance to disease prognosis.
Patients and Methods: This Study is a cross sectional study that was conducted on 55 patients newly diagnosed with chronic lymphocytic leukemia (CLL) in Clinical Hematology Unit in Ain-Shams University Hospitals in Cairo, Egypt. Result: The initial serum IL 6 level in the patient group (pre-treatment) ranged from 36-91pg/mL (median 57), and in the control group it ranged from 1-2 pg/mL (median 1).The initial serum IL 6 level in patient group (pre-treatment) range from 36-91 pg/mL (median 57), and in patient group (post treatment) range from 1-32 pg/mL (median 2).There are positive correlations between IL6 level and with WBC, B2 microglobulin, LDH, ESR, B symptoms, Uric Acid, BM Aspirate (% of lymphocytes)and Binet and Rai staging system.
Conclusion: Serum IL 6 is a useful poor prognostic marker in newly diagnosed CLL patients, its prognostic value goes with the other known prognostic markers as the lymphocytic count, ESR and LDH.